images

Roche’s neoadjuvant breast cancer combo therapy shows strong Phase 3 results

pharmafile | March 2, 2017 | News story | Research and Development Herceptin, Perjeta, Roche 

Roche’s combination treatment of Perjeta (pertuzumab), Herceptin (trasdtuzumab) and chemotherapy met its primary endpoint in a recent Phase 3 study. The therapy improved invasive disease-free survival (iDFS) in those with HER2-positive early breast cancer (eBC) when administered post-surgery, compared to Herceptin and chemotherapy alone.

Sandra Horning, Chief Medical Officer and Head of Global Product Development at Roche, commented on the findings, saying: “These results from the positive APHINITY study represent an important addition to the body of data for Perjeta in the treatment of people with HER2-positive early breast cancer. We look forward to discussing these adjuvant results with global regulatory authorities.”

The combination therapy is already licensed as a pre-surgery solution for the disease in 75 countries, and the post-therapy treatment is currently under the FDA’s accelerated approval; Roche hopes this promising new data will aid the treatment’s path to full approval.

Gunter von Minckwitz, Study Coordinator from the Breast International Group and academic study partners, added: “APHINITY provides yet another example of the importance of industry-academic collaborations and their value in advancing cancer care for people affected by this challenging disease.”

The aggressive HER2-positive breast cancer is known for poor prognoses and affects around 20% of breast cancer sufferers.

Matt Fellows

Related Content

Roche’s Alecensa approved by FDA as lung cancer treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …

Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …

Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn

Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …

Latest content